Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Meet the Evaluate Team: Alex Bour
Alex Bour leads Evaluate’s Competitive Intelligence consulting practice, working closely with clients to help them to understand the nuances of their competitive…
Quick View: Biopharma Dealmaking in Q3
The first half of the year showed some promise. Did the third quarter continue the trend? Well...
Digital Health and Biopharma: Different but the same
Digital health may be the new(ish) kid on the block of the wider pharma landscape, but in the past year or so it’s been through a pretty rapid maturity process. As with…
Q3 catalysts podcast: Evaluate Vantage hits the airwaves
Got time for a quick brain break? Listen to our podcast where we discuss the catalysts that will shape the third quarter of 2022.
Orphan drugs: about as niche as a flat white
To those beyond the world of biopharma, the term “orphan drug” sounds a bit sad, a bit forgotten. But to those involved in the industry, the superior return on…
Genetic Medicine: The Next Gene-eration
Once upon a time, a gene therapy player could release data on a handful of subjects and see its share price rocket. The sector was riding high after the landmark…